- Home
- NSSC vs TRVI Comparison
NSSC vs TRVI Comparison
Compare NSSC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSSC
- TRVI
- Stock Information
- Founded
- NSSC 1969
- TRVI 2011
- Country
- NSSC United States
- TRVI United States
- Employees
- NSSC N/A
- TRVI N/A
- Industry
- NSSC Telecommunications Equipment
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NSSC Telecommunications
- TRVI Health Care
- Exchange
- NSSC Nasdaq
- TRVI Nasdaq
- Market Cap
- NSSC 899.1M
- TRVI 725.7M
- IPO Year
- NSSC N/A
- TRVI 2019
- Fundamental
- Price
- NSSC $30.42
- TRVI $7.87
- Analyst Decision
- NSSC Strong Buy
- TRVI Strong Buy
- Analyst Count
- NSSC 6
- TRVI 9
- Target Price
- NSSC $34.50
- TRVI $19.94
- AVG Volume (30 Days)
- NSSC 259.2K
- TRVI 1.9M
- Earning Date
- NSSC 08-25-2025
- TRVI 08-07-2025
- Dividend Yield
- NSSC 1.85%
- TRVI N/A
- EPS Growth
- NSSC N/A
- TRVI N/A
- EPS
- NSSC 1.22
- TRVI N/A
- Revenue
- NSSC $181,227,000.00
- TRVI N/A
- Revenue This Year
- NSSC N/A
- TRVI N/A
- Revenue Next Year
- NSSC $6.02
- TRVI N/A
- P/E Ratio
- NSSC $24.82
- TRVI N/A
- Revenue Growth
- NSSC N/A
- TRVI N/A
- 52 Week Low
- NSSC $19.00
- TRVI $2.36
- 52 Week High
- NSSC $58.09
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- NSSC 55.53
- TRVI 74.32
- Support Level
- NSSC $29.55
- TRVI $6.67
- Resistance Level
- NSSC $30.91
- TRVI $8.11
- Average True Range (ATR)
- NSSC 0.70
- TRVI 0.41
- MACD
- NSSC -0.14
- TRVI 0.17
- Stochastic Oscillator
- NSSC 36.92
- TRVI 89.66
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.